| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
TERRY G. UNTERMAN
and
ROBERTA P. GLICK
Department of Obstetrics and Gynecology, Northwestern University Medical School Chicago, Illinois 60611
The Departments of Medicine, and Neurosurgery, University of Illinois College of Medicine, Veterans Administration West Side Medical Center, Cook County Hospital Chicago, Illinois 60611
Address requests for reprints to: Dr. R. Kazer, 333 East Superior Street, Suite 1502, Chicago, Illinois 60611.
To investigate the GH/insulin-like growth factor-I (IGF-I) axis in women with polycystic ovary syndrome (PCO), we measured serum concentrations of GH over a 14-h period (0900–2300 h) in 10 women with this disorder using an ambulatory exfusion pump. The same study was carried out in 9 age- and weight-matched normal cycling women who served as controls. Mean (±SE) serum GH concentrations over the 14-h period were markedly lower in the subjects with PCO (0.6 ± 0.2 vs. 1.8 ± 0.3 µg/L; P < 0.005). Eight of 10 subjects with PCO had mean serum GH concentrations below 1.2 µg/L, while only 1 of 9 control subjects had corresponding values below this concentration. In contrast, mean circulating serum concentrations of IGF-I were indistinguishable in the 2 groups.
We conclude from these data that PCO is characterized by decreased serum GH concentrations in the face of normal serum IGF-I concentrations. The mechanisms underlying this alteration in the GH/IGF-I axis and its role in the pathogenesis of PCO remain to be clarified.
* This work was supported in part by a grant (RR-00048) from the NIH, Division of Research Resources, and a Feasibility Grant from the American Diabetes Association.
Recipient of a Berlex Scholar Award.
Recipient of a Medical Research Career Development Award from the Department of Veteran Affairs.
Received February 14, 1990.
This article has been cited by other articles:
 |
|
 |
|
  J. A.M. de Boer, C. B. Lambalk, H. H. Hendriks, C. van Aken, E. A. van der Veen, and J. Schoemaker Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 504 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. C. M. van Dam, F. Roelfsema, F. H. Helmerhorst, M. Frolich, A. E. Meinders, J. D. Veldhuis, and H. Pijl Low Amplitude and Disorderly Spontaneous Growth Hormone Release in Obese Women with or without Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4225 - 4230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3496 - 3506. [Full Text]
|
|
|
|
|
|
Th. Kaltsas, N. Pontikides, G.E. Krassas, K. Seferiadis, D. Lolis, and I.E. Messinis Growth hormone response to thyrotrophin releasing hormone in women with polycystic ovarian syndrome Hum. Reprod., November 1, 1999; 14(11): 2704 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Carmina, F. Z. Stanczyk, R. S. Morris, P. D. K. Lee, G. Savjani, and R. A. Lobo Altered Regulation of Insulin-Like Growth Factor Binding Protein-I in Patients With Polycystic Ovary Syndrome Reproductive Sciences, November 1, 1995; 2(6): 743 - 747. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Franks Polycystic Ovary Syndrome N. Engl. J. Med., September 28, 1995; 333(13): 853 - 861. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
